Stanford researchers in the laboratory of Dr. Daria Mochly-Rosen have developed novel small molecules for modulating ALDH2 (mitochondrial aldehyde dehydrogenase-2).
Stanford researchers developed a first-in-class small-molecule inhibitor of the CLC-2 ion channel for research and drug development. CLC-2 is part of the CLC family of chloride ion channels, which regulate the flux of chloride ions across cell membranes.
Disease indication - Cancer, specifically:
-highly mutated cancers, including the ~20% of cancer with BAF complex mutations
-combination therapy with ATR inhibitors
Researchers in Prof. A.C. Matin's laboratory have developed a versatile exosome (extracellular vesicle, "EV") drug delivery platform that can selectively target therapeutic agents to tumors or other tissues that overexpress extracellular receptors.
Researchers at Stanford are developing methods of using arginine vasopressin (AVP) to improve social abilities of children with autism spectrum disorder (ASD). Autism is a neurodevelopmental disorder characterized by social impairments (e.g.
Researchers at Stanford have discovered new, chemically distinct opioid receptor ligands that may be used to develop safer opioid therapeutics. Opioids are ligands that bind to the mu, delta, and/or kappa opioid receptors.
Disease indication - HIV infection, specifically reversal of viral latency alone or in combination with other latency reversal agents to improve reservoir targeting.
Researchers in Dr. James Chen's lab at Stanford have discovered novel Hedgehog (Hh) pathway inhibitors that may serve as anti-cancer therapeutics. The Hh pathway plays a critical role in patterning, homeostasis, and oncogenic transformation of multiple tissues.
Stanford researchers have patented a photosynthetic system using a cyanobacterium solution that can be delivered to ischemic tissues, where blood flow is insufficient. This addresses a major clinical problem for patients with heart and vascular diseases.
The standard treatment for hepatitis C virus (HCV) is poorly tolerated and ineffective in a large subset of HCV patients. Scientists at Stanford and UCSF have developed new therapeutic leads for HCV that also have potential to be broad-spectrum anti-infectives.
FragFEATURE is a data-driven computational method for fragment binding prediction. It predicts small molecule fragments preferred by a protein structure using a knowledge base of all previously observed protein-fragment interactions.